The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC raised its position in The Cooper Companies, Inc. (NASDAQ:COO) by 6.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,634 shares of the medical device company’s stock after purchasing an additional 324 shares during the period. HighPoint Advisor Group LLC’s holdings in Cooper Companies were worth $526,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of COO. Norges Bank purchased a new stake in shares of Cooper Companies in the 4th quarter worth about $217,906,000. Raymond James Financial Inc. purchased a new stake in shares of Cooper Companies in the fourth quarter valued at about $64,826,000. Victory Capital Management Inc. grew its position in shares of Cooper Companies by 14.6% in the fourth quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock valued at $415,985,000 after purchasing an additional 574,899 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock worth $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Finally, Wealthfront Advisers LLC raised its position in shares of Cooper Companies by 4,594.1% during the 4th quarter. Wealthfront Advisers LLC now owns 569,812 shares of the medical device company’s stock worth $52,383,000 after purchasing an additional 557,673 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

COO has been the topic of a number of analyst reports. Robert W. Baird lowered their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Morgan Stanley decreased their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Wells Fargo & Company raised their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, Stifel Nicolaus reduced their price objective on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Stock Performance

Shares of COO stock opened at $81.23 on Thursday. The firm has a market capitalization of $16.24 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a 50 day moving average price of $88.59 and a 200 day moving average price of $96.72. The Cooper Companies, Inc. has a one year low of $77.05 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.